Published in J Virol on June 01, 1988
The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol (1992) 2.80
Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J Virol (1995) 2.58
Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol (1996) 2.41
Regulation of varicella-zoster virus gene expression in human T lymphocytes. J Virol (1992) 2.12
Varicella-zoster virus open reading frame 61 protein is functionally homologous to herpes simplex virus type 1 ICP0. J Virol (1992) 2.09
Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol (2002) 2.05
Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J Virol (1994) 1.99
The transcriptional regulatory proteins encoded by varicella-zoster virus open reading frames (ORFs) 4 and 63, but not ORF 61, are associated with purified virus particles. J Virol (1995) 1.84
The regions of the herpes simplex virus type 1 immediate early protein Vmw175 required for site specific DNA binding closely correspond to those involved in transcriptional regulation. Nucleic Acids Res (1988) 1.78
Varicella-zoster virus open reading frame 10 protein, the herpes simplex virus VP16 homolog, transactivates herpesvirus immediate-early gene promoters. J Virol (1993) 1.71
Characterization of regulatory functions of the varicella-zoster virus gene 63-encoded protein. J Virol (1992) 1.68
A major transactivator of varicella-zoster virus, the immediate-early protein IE62, contains a potent N-terminal activation domain. J Virol (1993) 1.59
Characterization of a potent varicella-zoster virus-encoded trans-repressor. J Virol (1991) 1.57
Varicella-zoster virus open reading frame 4 protein is functionally distinct from and does not complement its herpes simplex virus type 1 homolog, ICP27. J Virol (1994) 1.52
The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol (2009) 1.38
Characterization of the regulatory functions of varicella-zoster virus open reading frame 4 gene product. J Virol (1993) 1.30
The cellular transcription factor USF cooperates with varicella-zoster virus immediate-early protein 62 to symmetrically activate a bidirectional viral promoter. Mol Cell Biol (1994) 1.29
Virion association of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, requires expression of the VZV open reading frame 66 protein kinase. J Virol (2001) 1.27
Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J Virol (1996) 1.27
Phosphorylation of the varicella-zoster virus (VZV) major transcriptional regulatory protein IE62 by the VZV open reading frame 66 protein kinase. J Virol (2006) 1.15
The transcriptional activation domain of varicella-zoster virus open reading frame 62 protein is not conserved with its herpes simplex virus homolog. J Virol (1993) 1.07
Herpes simplex virus and varicella zoster virus, the house guests who never leave. Herpesviridae (2012) 1.04
The DNA binding domain of the varicella-zoster virus gene 62 protein interacts with multiple sequences which are similar to the binding site of the related protein of herpes simplex virus type 1. Nucleic Acids Res (1993) 1.03
The varicella-zoster virus genome. Curr Top Microbiol Immunol (2010) 1.02
Transcriptional mapping of the varicella-zoster virus regulatory genes encoding open reading frames 4 and 63. J Virol (1994) 1.02
Varicella-zoster virus open reading frame 21, which is expressed during latency, is essential for virus replication but dispensable for establishment of latency. J Virol (2003) 1.01
Varicella-zoster virus open reading frame 66 protein kinase is required for efficient viral growth in primary human corneal stromal fibroblast cells. J Virol (2008) 0.97
Mutational analysis of varicella-zoster virus major immediate-early protein IE62. Nucleic Acids Res (1995) 0.96
Varicella-zoster virus gene 21: transcriptional start site and promoter region. J Virol (1998) 0.93
Mutation of a single lysine residue severely impairs the DNA recognition and regulatory functions of the VZV gene 62 transactivator protein. Nucleic Acids Res (1994) 0.88
The DNA binding domains of the varicella-zoster virus gene 62 and herpes simplex virus type 1 ICP4 transactivator proteins heterodimerize and bind to DNA. Nucleic Acids Res (1994) 0.88
Identification of a promoter-specific transactivation domain in the herpes simplex virus regulatory protein ICP4. J Virol (1997) 0.87
Guinea pig cytomegalovirus immediate-early transcription. J Virol (1990) 0.83
An indole alkaloid from a tribal folklore inhibits immediate early event in HSV-2 infected cells with therapeutic efficacy in vaginally infected mice. PLoS One (2013) 0.78
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry (1979) 180.95
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet (1982) 54.79
Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol (1974) 26.25
The structure and evolution of the human beta-globin gene family. Cell (1980) 21.24
Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry (1974) 19.75
The complete DNA sequence of varicella-zoster virus. J Gen Virol (1986) 16.00
Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides. Proc Natl Acad Sci U S A (1975) 11.52
Two distinct transcription factors bind to the HSV thymidine kinase promoter in vitro. Cell (1985) 11.03
Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. J Virol (1980) 9.30
Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J Mol Biol (1984) 8.87
Characterization of the herpes simplex virion-associated factor responsible for the induction of alpha genes. J Virol (1983) 8.31
Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol (1985) 8.12
Structural features of the herpes simplex virus alpha gene 4, 0, and 27 promoter-regulatory sequences which confer alpha regulation on chimeric thymidine kinase genes. J Virol (1982) 7.35
Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J Virol (1985) 6.67
Cloning of herpes simplex virus type 1 sequences representing the whole genome. J Virol (1981) 5.66
Separation and characterization of herpes simplex virus type 1 immediate-early mRNA's. J Virol (1979) 5.21
The distal transcription signals of the herpesvirus tk gene share a common hexanucleotide control sequence. Cell (1984) 5.10
Temperature-sensitive mutants in herpes simplex virus type 1 ICP4 permissive for early gene expression. J Virol (1984) 3.76
Autoregulation of the human cytomegalovirus major immediate-early gene. J Virol (1985) 2.91
Structure of varicella-zoster virus DNA. J Virol (1981) 2.43
Replication origins and a sequence involved in coordinate induction of the immediate-early gene family are conserved in an intergenic region of herpes simplex virus. Nucleic Acids Res (1984) 2.35
Analysis of DNA sequences which regulate the transcription of herpes simplex virus immediate early gene 3: DNA sequences required for enhancer-like activity and response to trans-activation by a virion polypeptide. Nucleic Acids Res (1986) 2.08
Selective assay for herpes simplex viruses expressing thymidine kinase. J Virol (1979) 2.03
Identification of a varicella-zoster virus origin of DNA replication and its activation by herpes simplex virus type 1 gene products. J Gen Virol (1986) 1.96
Varicella-zoster virus complements herpes simplex virus type 1 temperature-sensitive mutants. J Virol (1987) 1.64
Characterization and nucleotide sequence of two herpes simplex virus 1 genes whose products modulate alpha-trans-inducing factor-dependent activation of alpha genes. J Virol (1987) 1.57
Transcription mapping of the varicella-zoster virus genome. J Virol (1985) 1.44
The immediate early proteins of varicella-zoster virus. Virology (1987) 1.39
Molecular cloning of the varicella-zoster virus genome and derivation of six restriction endonuclease maps. J Gen Virol (1983) 1.37
DNA sequences which regulate the expression of the pseudorabies virus major immediate early gene. Virology (1987) 1.37
Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide. J Virol (1988) 1.35
DNA sequence of the major inverted repeat in the varicella-zoster virus genome. J Gen Virol (1985) 1.28
Establishment of a rat cell line inducible for the expression of human cytomegalovirus immediate-early gene products by protein synthesis inhibition. J Virol (1986) 1.23
Expression of an immediate early polypeptide and activation of a viral origin of DNA replication in cells containing a fragment of herpes simplex virus DNA. Virology (1985) 1.16
Mutants defective in herpes simplex virus type 2 ICP4: isolation and preliminary characterization. J Virol (1987) 1.07
Mapping of the varicella zoster virus deoxypyrimidine kinase gene and preliminary identification of its transcript. Virology (1986) 1.02
The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med (1994) 26.24
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Chronic fatigue syndrome: a working case definition. Ann Intern Med (1988) 9.12
Finding and applying evidence during clinical rounds: the "evidence cart". JAMA (1998) 7.30
Socioeconomic status and health: what we know and what we don't. Ann N Y Acad Sci (1999) 6.96
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest (1998) 5.70
Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell (1995) 5.64
Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev (2005) 5.48
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 4.91
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 4.71
Concatemers of alternating plus and minus strands are intermediates in adenovirus-associated virus DNA synthesis. Proc Natl Acad Sci U S A (1976) 4.62
Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene "anti-sense" transcript by in situ hybridization. N Engl J Med (1987) 4.57
Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med (1996) 4.36
Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A (1988) 3.49
Personal health records: a scoping review. J Am Med Inform Assoc (2011) 3.41
Research into complementary and alternative medicine: problems and potential. BMJ (2001) 2.97
Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA (1998) 2.94
Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell (1999) 2.74
Varicella-zoster virus transcription in human trigeminal ganglia. Virology (1993) 2.63
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol (2001) 2.58
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Structure of varicella-zoster virus DNA. J Virol (1981) 2.43
Psychiatric diagnoses in patients who have chronic fatigue syndrome. J Clin Psychiatry (1989) 2.42
Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA (2001) 2.38
New enzyme immunoassays for measurement of influenza A/Victoria/3/75 virus in nasal washes. Lancet (1980) 2.35
Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med (1984) 2.26
Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med (1985) 2.25
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol (1999) 2.25
Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab (1991) 2.23
Mapping of two varicella-zoster virus-encoded genes that activate the expression of viral early and late genes. Virology (1989) 2.22
Propagation and in vitro studies of previously non-cultivable enteral adenoviruses in 293 cells. Lancet (1981) 2.18
Evidence based treatment of hypertension. Measurement of blood pressure: an evidence based review. BMJ (2001) 2.15
A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest (1992) 2.13
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med (1999) 2.11
Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood (1997) 2.10
Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood (2000) 2.09
Varicella-zoster virus open reading frame 61 protein is functionally homologous to herpes simplex virus type 1 ICP0. J Virol (1992) 2.09
Initiation of adenovirus DNA replication: detection of covalent complexes between nucleotide and the 80-kilodalton terminal protein. J Virol (1982) 2.07
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis (1999) 2.03
Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol (1990) 1.99
Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J Virol (1994) 1.99
Detection and preliminary characterization of herpes simplex virus type 1 transcripts in latently infected human trigeminal ganglia. J Virol (1988) 1.92
NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med (1988) 1.88
A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol (1994) 1.86
The medical review article revisited: has the science improved? Ann Intern Med (1999) 1.84
Stimulation of RNA synthesis in L-929 cells by rabbit tumor necrosis factor. Proc Soc Exp Biol Med (1979) 1.83
Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet (1999) 1.74
Varicella-zoster virus open reading frame 10 protein, the herpes simplex virus VP16 homolog, transactivates herpesvirus immediate-early gene promoters. J Virol (1993) 1.71
The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. J Infect Dis (1999) 1.70
Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. Virology (1994) 1.70
HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J Exp Med (1998) 1.66
Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus. Virology (1981) 1.65
Varicella-zoster virus complements herpes simplex virus type 1 temperature-sensitive mutants. J Virol (1987) 1.64
Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A (1987) 1.63
Transcripts of the adenovirus-associated virus genome: multiple polyadenylated RNAs including a potential primary transcript. J Virol (1980) 1.63
Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med (1995) 1.63
Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet (1991) 1.60
Molecular cloning and physical mapping of varicella-zoster virus DNA. Proc Natl Acad Sci U S A (1982) 1.60
A major transactivator of varicella-zoster virus, the immediate-early protein IE62, contains a potent N-terminal activation domain. J Virol (1993) 1.59
Genome differences among varicella-zoster virus isolates. J Gen Virol (1983) 1.59
Characterization of a potent varicella-zoster virus-encoded trans-repressor. J Virol (1991) 1.57
Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med (1993) 1.57
Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc Natl Acad Sci U S A (1999) 1.56
Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood (2001) 1.55
DNA-minus temperature-sensitive mutants of adenovirus type 5 help adenovirus-associated virus replication. J Virol (1975) 1.54
What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. Aust N Z J Psychiatry (2001) 1.51
NIH conference. Chronic fatigue syndrome research. Definition and medical outcome assessment. Ann Intern Med (1992) 1.50
Periodic illness associated with Epstein-Barr virus infection. Clin Infect Dis (1996) 1.49
Lack of association between HSV-1 DNA in the brain, Alzheimer's disease and apolipoprotein E4. J Neurovirol (2001) 1.48
Differential regulation by varicella-zoster virus (VZV) and herpes simplex virus type-1 trans-activating genes. Virology (1989) 1.47
Varicella-zoster virus (VZV) open reading frame 61 protein transactivates VZV gene promoters and enhances the infectivity of VZV DNA. J Virol (1993) 1.45
Transcription mapping of the varicella-zoster virus genome. J Virol (1985) 1.44
In utero diagnosis of congenital varicella zoster virus infection by chorionic villus sampling and polymerase chain reaction. Am J Obstet Gynecol (1991) 1.43
The UL37 protein of herpes simplex virus type 1 is associated with the tegument of purified virions. Virology (1995) 1.42
Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood (2001) 1.42
Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol (1998) 1.41
Recent advances in varicella-zoster virus infection. Ann Intern Med (1999) 1.41
Specificity and affinity of binding of herpes simplex virus type 2 glycoprotein B to glycosaminoglycans. J Virol (1997) 1.39
The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol (1998) 1.38
Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide. J Virol (1988) 1.35
Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J Infect Dis (1992) 1.35
Acyclovir-induced renal failure. Clinical course and histology. Am J Med (1988) 1.33
NIH Conference. Herpes simplex virus infection: biology, treatment, and prevention. Ann Intern Med (1985) 1.33
Varicella-zoster virus open reading frame 4 encodes a transcriptional activator that is functionally distinct from that of herpes simplex virus homology ICP27. J Virol (1994) 1.32
Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3' ends of labile mRNA. J Virol (1995) 1.32
Putative glycoprotein gene of varicella-zoster virus with variable copy numbers of a 42-base-pair repeat sequence has homology to herpes simplex virus glycoprotein C. J Virol (1986) 1.31